AIM-HIGH Logo

Presentations & Publications
AIM-HIGH Cholesterol Management Program
 
March 2011The AIM-HIGH InvestigatorsAIM-HIGH Design Paper The role of niacin in raising high-density lipoprotein cholesterol to reduce cardiovascular events in patients with atherosclerotic cardiovascular disease and optimally treated low-density lipoprotein cholesterol: rationale and study design. Am Heart J 2011;161(3):471.e2-477.e2
March 2011The AIM-HIGH InvestigatorsAIM-HIGH Baseline PaperThe role of niacin in raising high-density lipoprotein cholesterol to reduce cardiovascular events in patients with atherosclerotic cardiovascular disease and optimally treated low-density lipoprotein cholesterol: baseline characteristics of study participants Am Heart J 2011;161:538-43
Dec 2011The AIM-HIGH InvestigatorsNiacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy N Engl J Med 2011; 365:2255-2267
Jan 2012Boden, WE, Probstfield, JL.Interpreting the AIM-HIGH Trial Results: Insights and Implications for Clinical Practice CardioSource. January 3, 2012
Aug 2013Albers JJ, Slee A, O'Brien KD, Robinson JG, Kashyap ML, Kwiterovich PO Jr, Xu P, Marcovina SMRelationship of Apolipoproteins A-1 and B, and Lipoprotein (a) to Cardiovascular Outcomes in the AIM-HIGH Trial. J Am Coll Cardiol. 2013 Aug 7. doi:pii: S0735-1097(13)03076-3. 10.1016/j.jacc.2013.06.051. [Epub ahead of print] PubMed PMID: 23973688.
Aug 2013Guyton JR, Slee AE, Anderson T, Fleg JL, Goldberg RB, Kashyap ML, Marcovina SM, Nash SD, O'Brien KD, Weintraub WS, Xu P, Zhao XQ, Boden WERelationship of Lipoproteins to Cardiovascular Events in the Atherothrombosis Intervention in Metabolic Syndrome with Low HDL/High Triglycerides and Impact on Global Health Outcomes (AIM-HIGH) Trial. J Am Coll Cardiol. 2013 Jul 20. doi:pii: S0735 1097(13)02835-0. 10.1016/j.jacc.2013.07.023. [Epub ahead of print] PubMed PMID: 23916935.
Aug 2013Teo KK, Goldstein LB, Chaitman BR, Grant S, Weintraub, WS, Anderson DC, Sila CA, Cruz-Flores S, Padley RJ, Kostuk WJ, Boden WE on behalf of the AIM-HIGH InvestigatorsExtended-Release Niacin Therapy and Risk of Ischemic Stroke in Patients with Cardiovascular Disease: The Atherothrombosis Intervention in Metabolic Syndrome with Low HDL/High Triglycerides: Impact on Global Health Outcome (AIM-HIGH) Trial. Stroke. 2013;44:2688-2693; originally published online July 23, 2013

Funded by:

National Heart Lung and Blood Institute

 

Support from:
Abbott Laboratories